EMA Recommends Granting a Marketing Authorisation for Lurbinectedin By Ogkologos - April 30, 2026 281 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Cancer in Lymph Nodes May Help Tumors Spread by Enlisting Immune... May 27, 2022 Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows September 12, 2018 Combination of Nivolumab and Ipilimumab Yields Better Outcomes Compared to Ipilimumab... September 12, 2023 Adjuvant Dabrafenib Plus Trametinib Associated with Better RFS and DMFS than... July 9, 2024 Load more HOT NEWS The director’s cut: How Dr Catherine Elliott sees the future of... Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated... Early cancer diagnosis and COVID-19: unpicking the impact of the pandemic EMA Recommends Extension of Indications for Pembrolizumab
